Clinical Evidence: How Sucralfate Physically Shields Ulcers from Stomach Acid
By Sarah Jenkins
Choosing between mechanical mucosal protectants and systemic acid inhibitors involves distinct pharmacological trade-offs. The table below outlines how sucralfate compares to mainstays like PPIs and H2 blockers.
| Therapeutic Class | Primary Mechanism | Gastric pH Impact | Dosing Window | Systemic Absorption |
|---|---|---|---|---|
| Sucralfate (Carafate) | Mechanical electrostatic bandage; binds to damaged ulcer protein | None (requires acid to activate) | 1g four times daily on an empty stomach | Minimal (under 5% absorbed) |
| PPIs (e.g., Omeprazole) | Covalently binds and shuts down H+/K+ ATPase enzyme pumps | High suppression (elevates pH to 4.5, 6.0) | Once or twice daily before meals | High systemic distribution |
| H2 Blockers (e.g., Famotidine) | Reversibly blocks histamine H2 receptors on parietal cells | Moderate suppression (elevates pH temporarily) | Once or twice daily with or without food | Moderate systemic distribution |
Because sucralfate acts locally rather than systemically, it avoids disrupting nutrient absorption mechanisms that require stomach acid, such as vitamin B12, non-heme iron, and dietary calcium uptake.
Sarah Jenkins is a veteran tech journalist with over 12 years of experience covering artificial intelligence, mobile innovations, and digital ethics. Her insights have appeared in leading technology publications worldwide.
Tags:
sucralfate para que sirve
